Stem cell science in India: Emerging economies and the politics of globalization

Regenerative Medicine

Volumn 2, Issue 1, 2007, Pages 75-89

  Salter, Brian ^a   Cooper, Melinda ^a   Dickins, Amanda ^a   Cardo, Valentina ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Economics; Globalization; India; Politics

Indexed keywords

ARTICLE; BIOTECHNOLOGY; CELL THERAPY; DRUG INDUSTRY; EMBRYONIC STEM CELL; FINANCIAL MANAGEMENT; GOVERNMENT; INDIA; INTERNATIONAL COOPERATION; INVESTMENT; MARKETING; MASS MEDIUM; MEDICAL ETHICS; MEDICAL RESEARCH; PATENT; POLICY; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; RESEARCH ETHICS; SCIENTIST; STEM CELL; STRATEGIC PLANNING;

EMBRYO RESEARCH; EMBRYONIC STEM CELLS; INDIA; INTERNATIONAL COOPERATION; POLITICS; RESEARCH EMBRYO CREATION; STEM CELLS;

EID: 34249685484     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460751.2.1.75     Document Type: Article

References (43)

1. UK Stem Cell Initiative: Report and Recommendations. Department of Health, London, UK (2005).
2. Archibugi D, Michie J: Technology, Globalisation and Economic Performance. Cambridge University Press, Cambridge, UK (1997).
3. Levine AD: Research policy and the mobility of US stem cell scientists. Nat. Biotechnol. 24(7), 865-866 (2006).
4. Ross A: Fast Boat to China: Corporate Flight and the Consequences of Free Trade; Lessons from Shanghai. Pantheon, NY, USA (2006).
5. Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA (2006).
6. Smith RD: Foreign direct investment and trade in health services: a review of the literature. Soc. Sci. Med. 59, 2313-2323 (2004).
7. Enriquez J: Might a Bell Toll for US Pharma? Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Center, NY, USA 65-66 (2006).
8. Subramanian S: Chasing China: can India bridge the gap? In: Asia's Giants: Comparing China and India. Friedman E, Gilley B (Eds). Palgrave Macmillan, NY, USA 77-95 (2005).
9. Fitzgerald M: Where the money is. Nat. Biotechnol. 24, 240-242 (2006).
10. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A5-141 (2006).
11. Sur M: Breathing life into biology. Nature outlook: India. Nature 436, 487 (2005).
12. Jayaraman KS: Among the best. Nature outlook: India. Nature 436, 483 (2005).
13. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-122-A2-123 (2006).
14. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-32 (2006).
15. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A3-54-A3-55 (2006).
16. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A2-96 (2006).
17. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A5-97 (2006).
18. World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition). WIPO, 7 (2006).
19. World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition). WIPO, 10 (2006).
20. World Intellectual Property Organisation (WIPO): WIPO Patent Report. Statistics on Worldwide Patent Activity (2006 Edition). WIPO, 16 (2006).
21. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A6-53 (2006).
22. Kumar K, Quach U, Thorsteindottir H, Somsekhar H, Daar A, Singer P: Indian biotechnology - rapidly evolving and industry led. Nat. Biotechnol. 22(Suppl.), DC33 (2004).
23. National Science Board: Science and Engineering Indicators 2006. (Volume 2). National Science Foundation, Arlington, VA, USA A6-5-A6-9 (2006).
24. Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 55 (2006).
25. Padma TV: India's drug tests. Nature 436, 485 (2005).
26. Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA, 56 (2006).
27. National Science Board: Science and Engineering Indicators 2006. (Volume 2) National Science Foundation, Arlington, VA, USA A4-87 (2006).
28. Jayaraman KS: Biotech boom. Nature 436, 481 (2005).
29. The scientific balance of power. Nature 439(7077), 646-647 (2006).
30. Verma I: Then and now. Nature 436, 479 (2005).
31. Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 16-17 (2006).
32. Ernst and Young: Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry. Ernst and Young Global Pharmaceutical Centre, NY, USA 54 (2006).
33. Sethi S: Venture capital reforms: give me more on the platter. The Economic Times, 31 January (2001).
34. Bharadwaj A: Cultures of embryonic stem cell research in India. In: Crossing Borders. Cultural, Religious and Political Differences Concerning Stem Cell Research, a Global Approach. Bender W, Hauskeller, C, Manzei A (Eds). Agenda Verlag, Munster, Germany 331-333 (2005).
35. Bharadwaj A: Why adoption is not an option in India: the visibility of infertility, the secrecy of donor insemination, and other cultural complexities. Soc. Sci. Med. 56, 1867-1880 (2003).
36. Padma TV: India's drug tests. Nature 436, 485 (2005).
37. Padma TV: Rivalry and red tape. Nature 436, 490-491 (2005).
38. Mudur M: India plans to audit clinical trials. BMJ 331, 1044 (2005).
39. Padma TV. Unchecked by guidelines, Indian stem cell scientist rush ahead. Nat. Med. 12(1), 4 (2006).
40. Ramesh R: Row over doctor's 'miracle cures'. Guardian 18 November (2005).
41. Godall S, Janssens B, Wagner K, Wong J, Woods W, Yeh M: The promise of the East: India and China as R & D options. Nat. Biotechnol. 24(9), 1061-1064 (2006).
42. Mudur F: India plans to audit clinical trials. BMJ 331, 1044-1045 (2006).
43. Perrin N: The Global Commercialisation of UK Stem Cell Research. UKTI (2005).